Mizuho analyst Anthony Petrone lowered the firm’s price target on Staar Surgical (STAA) to $22 from $28 and keeps a Neutral rating on the shares. The firm says the company still has an uncertain path forward with a lack of clarity on China.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- STAAR Surgical Eyes 2026 Profit After Volatile Year
- Video: Moderna advances as settlement seen removing share overhang
- Morning Movers: Moderna rises after entering COVID settlement agreement
- Staar Surgical price target lowered to $18 from $19 at Stifel
- Staar Surgical: Short-Term Revenue Headwinds and 2026 Recovery Hopes Support Neutral Hold Rating